Clinical Trial

AHCC® as Immune Modulator in Cancer Patients Treated With Immunotherapy

Name: AHCC® as Immune Modulator in Cancer Patients Treated With Immunotherapy — clinical trial record (NCT07118735)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NCKUH

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This is a prospective, double-blind, randomized, placebo-controlled trial to evaluate whether AHCC® (Active Hexose Correlated Compound) can enhance the effect of immunotherapy in liver cancer patients.

Trial Details

NCT Number	NCT07118735
Lead Sponsor	National Cheng-Kung University Hospital
Conditions	Liver Cancer, Hepatocellular Carcinoma
Enrollment	94 participants
Start Date	2025-08-20
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-08-12